Pathogenesis and management of lipoatrophy

Area of Science:

• Medical research
• Pharmacology
• HIV/AIDS treatment

Background:

• Combination antiretroviral therapy (ART) significantly reduces HIV/AIDS mortality and morbidity.
• ART is associated with adverse events, notably lipoatrophy (subcutaneous fat wasting) and central fat accumulation.
• Mitochondrial toxicity is a suspected mechanism behind ART-related lipoatrophy.

Purpose of the Study:

• To review the challenges and potential interventions for ART-associated lipoatrophy.
• To highlight the limitations of current treatment strategies and the need for novel therapeutic approaches.

Main Methods:

• Review of existing studies on ART-related body fat abnormalities.
• Evaluation of therapeutic interventions including drug switches, thiazolidinediones, uridine, pravastatin, and facial fillers.
• Analysis of the efficacy and limitations of these interventions.

Main Results:

• Switching from nucleoside analogues shows modest, statistically significant increases in limb fat.
• Improvements from ART drug switches are slow, small, and not feasible for all patients.
• Clinical studies on thiazolidinediones for lipoatrophy have yielded conflicting results.

Conclusions:

• Current interventions for ART-associated lipoatrophy are insufficient.
• Further research into effective therapeutic strategies is crucial for managing this adverse event.
• Addressing lipoatrophy is essential for improving the long-term quality of life for patients on ART.